• Exelixis Inc., of South San Francisco, reported net product revenue for Cometriq (cabozantinib) of $4.8 million in the third quarter.

• Entremed Inc., of Rockville, Md., said it started a Phase II study, titled “Phase II Study of Oral ENDM-2076 Administered to Patients with Ovarian Clear Cell Carcinomas.”

• Algeta ASA, of Oslo, Norway, said partner Bayer AG, of Leverkusen, Germany, disclosed third-quarter 2013 U.S. net sales for Xofigo (radium Ra 223 dichloride) of €12 million (US$17 million).

Scientists have developed a method to shield transplanted cells from the transplant recipient’s immune system, enabling them to transplant a diabetic patient with insulin-producing islet cells that remained invisible to his immune system.